GRAIL, Inc.

What they do

GRAIL develops and sells Galleri, a multi-cancer early detection (MCED) test that analyzes methylation patterns of tumor-derived DNA in blood to detect a cancer signal and predict the organ or tissue of origin (Cancer Signal of Origin). The test is sold in the United States, launched in mid-2021, through healthcare systems, employers, digital health platforms, payors, international distributors, and life insurance providers. GRAIL also has a biopharmaceutical/development services business and has run clinical programs with data from over 385,000 participants.

Revenue drivers

• Galleri test revenue — The primary revenue source; Q2 2026 Galleri revenue was $42.6 million, up 24% year-over-year, within total revenue of $44.7 million.
• Development services revenue — A smaller biopharmaceutical/development services line; total revenue of $44.7 million less Galleri revenue of $42.6 million implies roughly $2.1 million in Q2 2026.
• Test volume growth — Revenue scales with Galleri tests sold; Q2 2026 volume exceeded 61,000 tests (up 35% year-over-year), and more than 117,000 tests were sold in the first half of 2026.

Recent performance

Q2 2026 total revenue was $44.7 million, up 26% year-over-year, with Galleri test revenue of $42.6 million, up 24%, and Galleri volume above 61,000 tests, up 35%. First-half 2026 Galleri revenue grew 30% to $82.5 million and volume grew 42% to more than 117,000 tests. Net loss for Q2 2026 was $110.2 million, an improvement of $3.7 million, while gross loss was $12.6 million and non-GAAP adjusted EBITDA was $(90.3) million. Cash, cash equivalents, and short-term marketable securities totaled $861.6 million as of June 30, 2026. Full-year revenue has grown from $93.1 million in 2023 to $125.6 million in 2024 and $147.2 million in 2025.

Strategy

GRAIL is pursuing FDA premarket approval (PMA) for Galleri, having submitted the final module in January 2026; the FDA accepted the application for review and management anticipates an advisory committee in fall 2026. It is investing in clinical evidence, including the approximately 35,000-participant PATHFINDER 2 study and the three-year randomized NHS-Galleri trial, and presented results at the 2026 ASCO Annual Meeting. The company completed a $110 million equity financing with Samsung and is expanding access through partnerships with healthcare systems, employers, digital health platforms, payors, international distributors, and life insurance providers. A restructuring plan approved by the Board reprioritizes resources on the core MCED business and reduces overall spend.

Risks

• Limited operating history and continuing losses — GRAIL began operations in January 2016, made its first Galleri sale in mid-2021, and has incurred significant net losses each period since inception.
• Dependence on Galleri — A substantial majority of revenue comes from Galleri sales, so the company is highly dependent on that single product.
• Reimbursement and payor coverage — If Galleri does not receive adequate coverage and reimbursement from third-party payors, expansion beyond existing sales channels and overall commercial success will be limited.
• Regulatory and clinical uncertainty — Galleri requires FDA PMA approval, and the clinical study process is lengthy, expensive, and uncertain, with possible delays or unexpected results that could affect launch, clearance, coverage, and reimbursement.

Outlook

Management says GRAIL continues to execute on clinical and commercial priorities and, following the January 2026 PMA submission, anticipates an FDA advisory committee in the fall. The company cites NHS-Galleri and PATHFINDER 2 results presented at ASCO 2026 as establishing Galleri as the only MCED with extensive clinical validation from interventional studies in the screening population. No specific revenue or earnings guidance is provided in the source excerpts.